XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.4
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Accounting Policies [Abstract]  
Summary of Segment Reconciliation All financial information required for segment reporting that is provided to the chief operating decision-maker is contained within the financial statements and notes to financial statements, with the exception of the disaggregated amounts contained in the table below:

 

 

 

Year Ended December 31,

 

(in thousands)

 

2025

 

 

2024

 

Research and development:

 

 

 

 

 

 

Salaries and staff costs

 

$

7,131

 

 

$

6,903

 

Stock-based compensation

 

 

2,376

 

 

 

1,660

 

Clinical trials, outside services, and lab supplies

 

 

23,954

 

 

 

26,472

 

Facilities and other

 

 

1,868

 

 

 

1,817

 

Total research and development

 

$

35,329

 

 

$

36,852

 

Selling, general and administrative:

 

 

 

 

 

 

Salaries and staff costs

 

$

3,973

 

 

$

3,286

 

Stock-based compensation

 

 

3,317

 

 

 

3,100

 

Outside services and professional fees

 

 

5,262

 

 

 

4,369

 

Facilities and other

 

 

1,672

 

 

 

1,727

 

Total selling, general and administrative

 

$

14,224

 

 

$

12,482

 

Useful Life of Property and Equipment The estimated useful lives of the major classes of property and equipment are as follows:

 

 

Estimated Useful Lives

Furniture and office equipment

3 to 5 years

Leasehold improvements

4 to 6 years

Laboratory equipment

5 years

Property and equipment consisted of the following:

(in thousands)

 

As of December 31,
2025

 

 

As of December 31,
2024

 

Furniture and office equipment

 

$

1,051

 

 

$

1,053

 

Leasehold improvements

 

 

2,568

 

 

 

2,568

 

Laboratory equipment

 

 

1,426

 

 

 

1,414

 

Property and equipment, gross

 

 

5,045

 

 

 

5,035

 

Less—accumulated depreciation

 

 

(4,467

)

 

 

(4,137

)

Property and equipment, net

 

$

578

 

 

$

898

 

Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:

 

 

 

December 31,

 

 

 

2025

 

 

2024

 

Options to purchase Common Stock

 

 

10,757,293

 

 

 

8,334,765

 

Warrants to purchase Common Stock

 

 

432

 

 

 

2,807,353

 

Series A Convertible Preferred Stock

 

 

877

 

 

 

877

 

 

 

10,758,602

 

 

 

11,142,995